Endothelin (ET) is a recently discovered 21 ... The effects of ET are mediated through interaction with two classes of cell surface receptors. The type A receptor (ET-A) has been associated ...

Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist ...

Researchers at University of Tsukuba used cryo-electron microscopy to examine the complex structure of the endothelin receptor and G protein, which are crucial for signal transduction at the cell ...

Article Google Scholar Ogawa Y, Nakao K, Arai H, Nakawaga O, Hosoda K, Suga SI, Nakanishi S, Imura H: Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biophys Biochem ...

Preclinical Development Updates F230: F230 is a selective endothelin receptor agonist for the treatment of pulmonary arterial hypertension ("PAH”). In May 2024, Gyre Pharmaceuticals received NMPA ...

Adding Uptravi (selexipag) to standard-of-care PAH treatment within six months may reduce the risk of hospitalization, per a ...

A team of researchers led by Duke University, the University of California San Francisco, and the Beckman Research Institute of the City of Hope have engineered odorant receptors to reveal the ...

The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in reducing proteinuria in patients with IgA nephropathy are incompletely understood. We are conducting a ...

Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of ...

One type of drug used to treat PAH is endothelin receptor antagonists. ERAs, as they are called, help keep blood vessels from narrowing. But these drugs don’t work as well for Black patients as ...